A single-center retrospective cohort study of Covid-19 medications: Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon β1a and their combinations

DOI record: { "DOI": "10.1101/2021.03.05.21251351", "URL": "http://dx.doi.org/10.1101/2021.03.05.21251351", "abstract": "<jats:title>Abstract</jats:title><jats:p>Many drugs have been suggested to be used for Covid-19. A suitable and efficient choice of drug would make the course of Covid-19 easier. we have investigated the efficacy of different treatment regimen in reducing hospitalization period (HP) and mortality of 324 confirmed Covid-19 patients. Received drugs included single therapy or combinations of Methylprednisolone, Remdesivir, Favipiravir, Interferon β1a, and Dexamethasone. HP and mortality were compared between different treatment groups to evaluate efficacy of each drug. HP and mortality were also calculated for patients in each treatment group based on their underlying diseases and age. we suggest that using IFN-β1a, RDV and corticosteroids might not have a significant effect on the HP or mortality of the Covid-19 patients as it was thought before.</jats:p>", "accepted": { "date-parts": [ [ 2021, 3, 8 ] ] }, "author": [ { "affiliation": [], "family": "Fateh", "given": "Sahand Tehrani", "sequence": "first" }, { "affiliation": [], "family": "Fateh", "given": "Sepand Tehrani", "sequence": "additional" }, { "affiliation": [], "family": "Salehi", "given": "Esmaeil", "sequence": "additional" }, { "affiliation": [], "family": "Rezai", "given": "Nima", "sequence": "additional" }, { "affiliation": [], "family": "Haririan", "given": "Nazanin", "sequence": "additional" }, { "affiliation": [], "family": "Asgari", "given": "Abdollah", "sequence": "additional" }, { "affiliation": [], "family": "Salehi-Najafabadi", "given": "Amir", "sequence": "additional" } ], "container-title": [], "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2021, 3, 8 ] ], "date-time": "2021-03-08T17:45:19Z", "timestamp": 1615225519000 }, "deposited": { "date-parts": [ [ 2021, 3, 10 ] ], "date-time": "2021-03-10T18:10:41Z", "timestamp": 1615399841000 }, "group-title": "Infectious Diseases (except HIV/AIDS)", "indexed": { "date-parts": [ [ 2022, 4, 2 ] ], "date-time": "2022-04-02T05:54:28Z", "timestamp": 1648878868157 }, "institution": [ { "name": "medRxiv" } ], "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2021, 3, 8 ] ] }, "link": [ { "URL": "https://syndication.highwire.org/content/doi/10.1101/2021.03.05.21251351", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "246", "original-title": [], "posted": { "date-parts": [ [ 2021, 3, 8 ] ] }, "prefix": "10.1101", "published": { "date-parts": [ [ 2021, 3, 8 ] ] }, "publisher": "Cold Spring Harbor Laboratory", "reference": [ { "DOI": "10.1016/S1473-3099(20)30120-1", "doi-asserted-by": "publisher", "key": "2021031010100751000_2021.03.05.21251351v1.1" }, { "DOI": "10.1016/j.cmi.2020.05.019", "article-title": "Review of trials currently testing treatment and prevention of COVID-19", "doi-asserted-by": "crossref", "first-page": "988", "journal-title": "Clin. Microbiol. Infect", "key": "2021031010100751000_2021.03.05.21251351v1.2", "volume": "26", "year": "2020" }, { "DOI": "10.1371/journal.pone.0232391", "doi-asserted-by": "publisher", "key": "2021031010100751000_2021.03.05.21251351v1.3" }, { "DOI": "10.1002/jmv.26302", "doi-asserted-by": "publisher", "key": "2021031010100751000_2021.03.05.21251351v1.4" }, { "DOI": "10.1016/j.micinf.2020.05.012", "article-title": "Arbidol/IFN-α2b therapy for patients with coronavirus disease 2019: a retrospective multicenter cohort study", "doi-asserted-by": "crossref", "first-page": "200", "journal-title": "Microbes Infect", "key": "2021031010100751000_2021.03.05.21251351v1.5", "volume": "22", "year": "2020" }, { "DOI": "10.1101/2020.03.17.20037432", "doi-asserted-by": "publisher", "key": "2021031010100751000_2021.03.05.21251351v1.6" }, { "DOI": "10.1016/j.eng.2020.03.007", "doi-asserted-by": "publisher", "key": "2021031010100751000_2021.03.05.21251351v1.7" }, { "DOI": "10.1101/2020.05.04.20074609", "doi-asserted-by": "crossref", "key": "2021031010100751000_2021.03.05.21251351v1.8", "unstructured": "Fadel Raef, A. M. Early Short Course Corticosteroids in Hospitalized Patients with COVID-19. (2020)." }, { "DOI": "10.1101/2020.05.11.20097709", "doi-asserted-by": "publisher", "key": "2021031010100751000_2021.03.05.21251351v1.9" }, { "key": "2021031010100751000_2021.03.05.21251351v1.10", "unstructured": "R Core Team. R: A Language and Environment for Statistical Computing. (2020)." }, { "key": "2021031010100751000_2021.03.05.21251351v1.11", "unstructured": "RStudio Team. RStudio: Integrated Development Environment for R. (2020)." }, { "DOI": "10.1021/acs.jmedchem.6b01594", "doi-asserted-by": "publisher", "key": "2021031010100751000_2021.03.05.21251351v1.12" }, { "key": "2021031010100751000_2021.03.05.21251351v1.13", "unstructured": "USFoodandDrugAdministration. Coronavirus (COVID-19) update: FDA issues Emergency Use Authorization for potential COVID-19 treatment. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment (2020)." }, { "DOI": "10.1056/nejmoa2007764", "doi-asserted-by": "publisher", "key": "2021031010100751000_2021.03.05.21251351v1.14" }, { "DOI": "10.1016/S0140-6736(20)31022-9", "doi-asserted-by": "publisher", "key": "2021031010100751000_2021.03.05.21251351v1.15" }, { "DOI": "10.1001/jama.2020.16349", "article-title": "Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial", "doi-asserted-by": "crossref", "first-page": "1048", "journal-title": "JAMA - J. Am. Med. Assoc", "key": "2021031010100751000_2021.03.05.21251351v1.16", "volume": "324", "year": "2020" }, { "article-title": "Remdesivir for 5 or 10 Days in Patients with Severe Covid-19", "first-page": "2019", "journal-title": "N. Engl. J. Med", "key": "2021031010100751000_2021.03.05.21251351v1.17", "volume": "2019", "year": "2020" }, { "DOI": "10.2183/pjab.93.027", "doi-asserted-by": "publisher", "key": "2021031010100751000_2021.03.05.21251351v1.18" }, { "DOI": "10.1016/j.ejps.2020.105631", "doi-asserted-by": "publisher", "key": "2021031010100751000_2021.03.05.21251351v1.19" }, { "DOI": "10.1111/resp.13196", "doi-asserted-by": "publisher", "key": "2021031010100751000_2021.03.05.21251351v1.20" }, { "first-page": "1", "journal-title": "Interferon-β 1a inhibits SARS-CoV-2 in vitro when administered after virus infection Nicola", "key": "2021031010100751000_2021.03.05.21251351v1.21", "volume": "6", "year": "2018" }, { "DOI": "10.1128/AAC.01061-20", "doi-asserted-by": "crossref", "key": "2021031010100751000_2021.03.05.21251351v1.22", "unstructured": "Davoudi-Monfared, E. et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob. Agents Chemother. 64, (2020)." }, { "article-title": "Interferon beta-1a as a Candidate for COVID-19 Treatment;An Open-Label Single-Arm Clinical Trial", "first-page": "1", "journal-title": "Adv. J. Emerg. Med", "key": "2021031010100751000_2021.03.05.21251351v1.23", "volume": "4", "year": "2020" }, { "DOI": "10.1016/j.intimp.2020.106688", "article-title": "Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial", "doi-asserted-by": "crossref", "first-page": "106688", "journal-title": "Int. Immunopharmacol", "key": "2021031010100751000_2021.03.05.21251351v1.24", "volume": "85", "year": "2020" }, { "DOI": "10.1016/j.ijantimicag.2020.106077", "doi-asserted-by": "crossref", "key": "2021031010100751000_2021.03.05.21251351v1.25", "unstructured": "Bani-Sadr, F. et al. Corticosteroid therapy for patients with COVID-19 pneumonia: a before-after study. Int. J. Antimicrob. Agents 56, (2020)." }, { "DOI": "10.1080/17476348.2020.1804365", "article-title": "Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis", "doi-asserted-by": "crossref", "first-page": "1149", "journal-title": "Expert Rev. Respir. Med", "key": "2021031010100751000_2021.03.05.21251351v1.26", "volume": "14", "year": "2020" }, { "DOI": "10.3390/jcm9082392", "article-title": "Efficacy of Corticosteroids in Patients with SARS, MERS and COVID-19: A Systematic Review and Meta-Analysis", "doi-asserted-by": "crossref", "first-page": "2392", "journal-title": "J. Clin. Med", "key": "2021031010100751000_2021.03.05.21251351v1.27", "volume": "9", "year": "2020" }, { "DOI": "10.1001/jama.2020.17023", "article-title": "Association between Administration of Systemic Corticosteroids and Mortality among Critically Ill Patients with COVID-19: A Meta-analysis", "doi-asserted-by": "crossref", "first-page": "1330", "journal-title": "JAMA - J. Am. Med. Assoc", "key": "2021031010100751000_2021.03.05.21251351v1.28", "volume": "324", "year": "2020" }, { "DOI": "10.1001/jama.2020.17022", "article-title": "Effect of Hydrocortisone on Mortality and Organ Support in Patients with Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial", "doi-asserted-by": "crossref", "first-page": "1317", "journal-title": "JAMA - J. Am. Med. Assoc", "key": "2021031010100751000_2021.03.05.21251351v1.29", "volume": "324", "year": "2020" }, { "DOI": "10.3389/fpubh.2020.00355", "doi-asserted-by": "crossref", "key": "2021031010100751000_2021.03.05.21251351v1.30", "unstructured": "Hu, Z. et al. Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia Progression. Front. Public Heal. 8, (2020)." }, { "DOI": "10.1038/s41422-020-0282-0", "doi-asserted-by": "publisher", "key": "2021031010100751000_2021.03.05.21251351v1.31" }, { "DOI": "10.5694/mja2.50577", "article-title": "Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19)", "doi-asserted-by": "crossref", "first-page": "416", "journal-title": "Med. J. Aust", "key": "2021031010100751000_2021.03.05.21251351v1.32", "volume": "212", "year": "2020" }, { "DOI": "10.1101/2020.04.17.20069773", "doi-asserted-by": "crossref", "key": "2021031010100751000_2021.03.05.21251351v1.33", "unstructured": "Gangopadhyay, K. K. et al. Title Page Title : The role of corticosteroids in the management of critically ill patients with coronavirus disease 2019 (COVID-19): A meta-analysis Author details : Abstract Objective : Data Sources : Data extraction : Data synthesis: (2020)." }, { "DOI": "10.1101/2020.08.13.20174201", "doi-asserted-by": "crossref", "key": "2021031010100751000_2021.03.05.21251351v1.34", "unstructured": "Tlayjeh, H. et al. Efficacy of Corticosteroids in COVID-19 Patients: A Systematic Review and Meta-Analysis. medRxiv (2020)." }, { "DOI": "10.1007/s40121-020-00332-3", "doi-asserted-by": "publisher", "key": "2021031010100751000_2021.03.05.21251351v1.35" }, { "DOI": "10.1371/journal.pone.0232391", "doi-asserted-by": "publisher", "key": "2021031010100751000_2021.03.05.21251351v1.36" }, { "DOI": "10.1038/s41598-020-59121-0", "doi-asserted-by": "publisher", "key": "2021031010100751000_2021.03.05.21251351v1.37" } ], "reference-count": 37, "references-count": 37, "relation": {}, "resource": { "primary": { "URL": "http://medrxiv.org/lookup/doi/10.1101/2021.03.05.21251351" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "subtype": "preprint", "title": "A single-center retrospective cohort study of Covid-19 medications: Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon β1a and their combinations", "type": "posted-content" }